XML 26 R15.htm IDEA: XBRL DOCUMENT v3.25.3
Financial Instruments
 9 Months Ended
Sep. 30, 2025
Investments, All Other Investments [Abstract]  
Financial Instruments

Note 9. Financial Instruments

 

Cash, Note payable, related party

 

The following tables show the Company’s cash, cash equivalents, restricted cash, and note payable, related party by significant investment category as of:

 

   September 30, 2025 
  

Adjusted

Cost

  

Unrealized

(Gain)/Loss

  

Fair

Value

  

Cash and

Cash

Equivalents

   Note Payable, Related Party 
Level 1                         
Cash  $12,000   $-   $12,000   $12,000   $- 
Level 2                         
Note payable, related party   14,738,000    8,143,000    22,881,000    -    22,881,000 
Total  $14,750,000   $8,143,000   $22,893,000   $12,000   $22,881,000 

 

   December 31, 2024 
   Adjusted
Cost		   Unrealized
(Gain)/Loss		   Fair
Value		   Cash and
Cash
Equivalents		   Note Payable, Related Party 
Level 1                    
Cash  $1,999,000   $-   $1,999,000   $1,999,000   $- 
Level 2                         
Note payable, related party   13,946,000    (5,068,000)   8,878,000    -    8,878,000 
Total  $15,945,000   $(5,068,000)  $10,877,000   $1,999,000   $8,878,000 

 

 

Impact Biomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements